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Abstract
Many G-protein coupled receptors (GPCRs), such as odorant receptors (ORs), cannot be
characterized in heterologous cells because of their difficulty in trafficking to the plasma
membrane. In contrast, a surrogate OR, the GPCRmouse β2-adrenergic-receptor
(mβ2AR), robustly traffics to the plasma membrane. We set out to characterize mβ2AR
mutants in vitro for their eventual use in olfactory axon guidance studies. We performed an
extensive mutational analysis of mβ2AR using a Green Fluorescent Protein-tagged mβ2AR
(mβ2AR::GFP) to easily assess the extent of its plasma membrane localization. In order to
characterize mutants for their ability to successfully transduce ligand-initiated signal cas-
cades, we determined the half maximal effective concentrations (EC50) and maximal
response to isoprenaline, a known mβ2AR agonist. Our analysis reveals that removal of
amino terminal (Nt) N-glycosylation sites and the carboxy terminal (Ct) palmitoylation site of
mβ2AR do not affect its plasma membrane localization. By contrast, when both the Nt and
Ct of mβ2AR are replaced with those of M71 OR, plasma membrane trafficking is impaired.
We further analyze three mβ2AR mutants (RDY, E268A, and C327R) used in olfactory
axon guidance studies and are able to decorrelate their plasma membrane trafficking with
their capacity to respond to isoprenaline. A deletion of the Ct prevents proper trafficking and
abolishes activity, but plasma membrane trafficking can be selectively rescued by a Tyro-
sine to Alanine mutation in the highly conserved GPCRmotif NPxxY. This new loss-of-func-
tion mutant argues for a model in which residues located at the end of transmembrane
domain 7 can act as a retention signal when unmasked. Additionally, to our surprise,
amongst our set of mutations only Ct mutations appear to lower mβ2AR EC50s revealing
their critical role in G-protein coupling. We propose that an interaction between the Nt and
Ct is necessary for proper folding and/or transport of GPCRs.
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Introduction
G-Protein Coupled Receptors (GPCRs) are the largest and most ubiquitous family of plasma
membrane receptors. They are involved in almost all physiological processes in humans, such
as the sensory systems of vision, taste and smell [1]. GPCRs are the most common targets of
therapeutic drugs, including blockers and agonists of α and β-adrenergic receptors, dopamine
receptors, serotonin receptors, histamine receptors and opioid receptors. Twenty-five percent
of the top 200 therapeutics and over fifty percent of all therapeutics, target GPCRs [2]. By con-
trast, thousands of odorant receptors have been identified, but odor to receptor pairings have
not been characterized, thus limiting the study of olfaction.
The GPCRs rhodopsin and the β2-adrenergic-receptor (β2AR) have been crystallized and
extensively studied at the biochemical level, yet the vast majority of GPCR structures are unde-
fined and their ligands remain poorly understood or unknown [3]. This is mainly due to the
lack of an effective heterologous cell culture system to express GPCRs and perform high-
throughput ligand binding analysis [4]. GPCRs that do not functionally express in vitro, fail to
traffic to the plasma membrane and remain trapped in intracellular compartments [5, 6]. In
contrast, some GPCRs successfully traffic to the plasma membrane of heterologous cells, like
the canonical β2AR. The properties of GPCRs that govern trafficking to the plasma membrane
are still largely unknown and mutants are rarely tested in vivo. Ironically, because the β2AR
robustly traffics to the plasma membrane, its synthesis and insertion into the plasma mem-
brane has not been the subject of experimentation. Most efforts have primarily focused on the
dynamics of β2AR ligand activation.
Remarkably, when expressed from an OR locus in mouse olfactory neurons, the mouse
β2AR (mβ2AR) can substitute for all functions of an OR: preventing expression of another OR,
maturation of the neurons, axonal outgrowth and convergence of the axons into an homoge-
nous ectopic glomerulus in the olfactory bulb [7]. In addition, human β2AR (hβ2AR)
expressed in mouse olfactory neurons also fulfills all functions of ORs [8–10]. Hence mouse
and human β2ARs can be used as OR surrogates.
To further characterize the properties of surrogate OR β2AR, we have conducted a muta-
tional analysis to determine the features necessary for trafficking to the plasma membrane and
β2AR functionality. Because β2AR normally traffics to the plasma membrane in heterologous
cells, we worked backwards to determine what sequences were necessary for β2AR to function
and what sequences on the non-trafficking M71 OR might “kill β2AR” trafficking and func-
tion. In a parallel study, we have also tried to “fix M71” using the opposite strategy of imparting
functionality from β2AR sequences onto M71 OR [11].
Previous studies have successfully used chimeric GPCRs of the homologous receptors α2
and β2AR to identify domains involved in coupling to G-proteins and ligand binding [12], but
this strategy has not been implemented to define domains critical for plasma membrane traf-
ficking. Other groups have used chimeric analyses to rescue non-trafficking GPCRs with traf-
ficking GPCRs, but here we are taking the reciprocal approach by replacing domains of a
trafficking GPCR with domains of a non-trafficking GPCR [5].
We performed a mutational analysis to test the role of N-linked glycosylation of the β2AR
amino-terminus (Nt) on its trafficking capacity; we modified mβ2AR so that its primary
sequence is analogous to a non-trafficking GPCR, the M71 OR, to test if the length of the Nt
and/or Ct were factors involved in trafficking; we defined the role of the minimal Ct and chi-
meras with M71 OR on proper β2AR trafficking and activity. Finally, we analyzed known
mβ2AR activity mutants on their in vitro trafficking defects. Over 30 mutants were analyzed.
The workflow of this mutagenesis is summarized in Fig 1A.
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Fig 1. Mutational analysis for the β2 adrenergic receptor. (A) Workflow schematic of the mutational analysis for the β2 adrenergic receptor. First step was
to reduce the primary sequence of the mouse β2AR (mβ2AR) to that of the non-trafficking odorant receptor M71. Then we asked what is the C-terminus
minimal requirement for trafficking and activity by analyzing Ct truncations series as well as Ct full deletion. Furthermore we analyzed the effects of mutating a
putative retention signal that might be revealed by a Ct deletion. We also compared the phenotype of mouse and human β2AR activity mutants to M71.
Finally, we analyzed the behavior of M71/mβ2AR chimera. (B) The 2D topology of mouse β2AR was generated using the online software Topo2 (see
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Our analysis has identified key elements for plasma membrane trafficking and function for
the mβ2AR that are potentially obscured in other non-trafficking GPCRs. Targeting these fea-
tures necessary for GPCR functionality could help generate new tools for the study of olfactory
function, and unravel new potential targets for therapeutics.
Material and Methods
Plasmid constructions
Mutant versions of human β2AR, mouse β2AR and M71 (Olfr151, codon optimized) were gen-
erated either by PCR with ultramer primers (Integrated DNA Technologies), QuickChange
mutagenesis (Agilent Technologies) or Gibson Assembly Cloning (New England Biolabs Inc).
See supplementary materials for DNA and protein sequences of mouse β2AR, human β2AR,
M71, linker, GFP and mCherry (S1 Text). All constructs were verified through sequencing for
the GPCR sequence, linker and proper phase with the fluorophore sequence.
2D topology of mouse β2AR and M71 were generated using the online software Topo2
(Johns S.J., TOPO2, Transmembrane protein display software, http://www.sacs.ucsf.edu/
TOPO2/). The following putative transmembrane domain locations were used for mouse
β2AR: TM1 35–58, TM2 72–95, TM3 107–130, TM4 151–174, TM5 197–220, TM6 275–298
and TM7 306–329; and the following for the mouse M71: TM1 29–49, TM2 57–77, TM3 91–
111, TM4 134–154, TM5 196–216, TM6 239–259 and TM7 271–291.
RTP1S was amplified from mouse olfactory cDNA with 5’ aaaagagctcaagcttcga
attcggcgcgccaccatgtgtaagagtgtga 3’ and 5’ ttaattaatcagacagaagtacgg
aaggagaat 3’ primers, shuttled into the pGemT Easy vector (Promega). RTP1S clone was
only used for the trafficking experiments in OP6 cells.
OP6 cell culture and transfection
Olfactory placode 6 (OP6 [13], a gift from Jane Roskams) cells were grown in DMEM (Invitro-
gen), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, at
33°C in a humidified 5% CO2 atmosphere and passaged at regular intervals, after dissociation
with trypsin 0.05%-EDTA. Cells were transiently transfected with 10μg of DNA using Amaxa
Nucleofector technology (Lonza, program COS-7 DSMZ) and plated onto 60mm round dishes.
Twenty-four hours after transfection, cells were imaged directly with an immersion 25X lens
and a Zeiss 510 laser scanning confocal microscope.
GFP-labeled filopodia counts
For each GFP fusion construct, 10 cells were randomly selected and GFP-labeled filopodia
were counted. Confocal pictures of cells were calibrated to non-saturating images of mβ2AR::
GFP. These settings were used for all subsequent images. Average and standard deviation were
calculated. To assess the difference in mean filopodia counts across all samples, one-way analy-
sis of variance (ANOVA) was performed using the MATLAB anova1 function, with an
alpha = 0.001 and Scheffe post hoc tests. Mutants were categorized into groups based on their
function as described in figures and ANOVA was run on each group with the addition of the
M71::GFP construct as a negative control. Thus, error rates are a function of grouping.
Material & Methods). Plasmamembrane is symbolized by two horizontal lines with the extracellular compartment on top and intracellular compartment on the
bottom. Putative transmembrane domains are located in between those two lines. Different shapes and colors are used to symbolize the residues targeted
for mutations. N-linked glycosylation sites are indicated in black boxes and their N in diamonds.
doi:10.1371/journal.pone.0141696.g001
In VitroMutational Analysis of the β2 Adrenergic Receptor
PLOS ONE | DOI:10.1371/journal.pone.0141696 October 29, 2015 4 / 28
CellMask plasma membrane staining
Cellmask Deep Red Plasma Membrane reagent (Life Technologies) was briefly centrifuged and
diluted 1/1000 in FluoroBrite DMEM (Life Technologies). Twenty-four hours after transfec-
tion (see above) and prior to imaging, cells were washed once with FluoroBrite DMEM. Cells
were then stained with the diluted reagent for 7 minutes in the incubator at 33°C. After 7 min-
utes, cells were washed 3 times in FluoroBrite DMEM and imaged directly using a 25X immer-
sion lens and a Zeiss LSM 510 confocal microscope.
Dose Response Curves to isoprenaline
Calcium-based Fluorometric Imaging Plate Reader (FLIPR) experiments were performed as
described previously [14]. Mutants analyzed in each figure come from the same FLIPR experi-
ment. Stock transfection and isoprenaline solutions were prepared for each experiment to
ensure the same quantity of human G-alpha15 expression and dilution of isoprenaline. Relative
Fluorescent Units were baseline corrected by subtracting the lowest fluorescent measure for
each experiment and a curve was fitted using a 3 parameters model (Hill Slope = 1) using the
GraphPad software. Half maximal effective concentrations (EC50) were then calculated and
are given in nM. The maximum response, as a percent of wild type, was calculated by reporting
the span for a mutant over the span for the wild type.
Results
Plasma membrane localization of gap::GFP measured by GFP-labeled
filopodia counts
To assess plasma membrane trafficking of odorant receptors, and other GPCRs, we have
employed OP6 cells that are derived from the mouse olfactory placode [13, 15, 16]. These neu-
ronal derived immortal cell lines naturally exhibit many filopodia—thin extensions (0.1–0.3μm
diameter) from the plasma membrane mostly composed of actin filaments [17, 18]. The
reduced cytoplasm fraction creates a differential between diffusion-limited cytoplasmic pro-
teins and other protein types capable of localizing within filopodia. Indeed we previously
showed that untagged GFP and six other fluorescent protein variants (XFPs) rarely enter filo-
podia [14].
To further characterize this differential localization we compared the total number of filopo-
dia that can be observed in a cell with the number of GFP-labeled filopodia. We show that
untagged GFP fluorescence (Fig 2A) is found only in a few filopodia per cell expressing cyto-
solic GFP (Fig 2E). We further quantified this feature by determining how many cells show a
complete absence or a single GFP-labeled filopodia (1). In this latter analysis, untagged GFP
was observed in1 filopodia in 4/10 cells (blue diamond in Fig 2E). By contrast, with simulta-
neous staining of the plasma membrane, using the CellMask Deep Red plasma membrane
stain, we observe 44.7 ±15.9 filopodia per cell, confirming their presence, but only 2.6 ±3.2
GFP-labeled filopodia (Fig 2A’ and 2F). Thus, the lack of observable GFP-labeled filopodia in
cells expressing GFP is a consequence of the inability of untagged GFP to contribute to its cyto-
plasmic fraction.
In contrast, when GFP is fused to a membrane targeting tag that contains a palmitoylation
site from the Zebrafish Gap43 (20 amino acids, gap::GFP), it shows sharp edge expression on
all cells (Fig 2B) and we observe many GFP-labeled filopodia per cell (Fig 2E). None of these
cells have1 GFP-labeled filopodia (Fig 2E). When this experiment is repeated with CellMask
staining, all 33.6 ±9.9 filopodia per cell are completely co-labeled with gap::GFP (Fig 2B’ and
2F). Importantly, total CellMask filopodia counts between OP6 cells expressing untagged GFP
In VitroMutational Analysis of the β2 Adrenergic Receptor
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Fig 2. Expression of GFP and GPCR::GFP in OP6 cells. (A) Cytosolic GFP shows diffuse fluorescence in the cytoplasm of an OP6 cell and does not co-
localize with the plasmamembrane staining CellMask Deep Red in filopodia (A’, arrow head in magnified image). (B) On the contrary, gap::GFP, shows a
sharp edge staining of a whole OP6 cell and co-localize with the plasmamembrane staining CellMask Deep Red in filopodia (B’, arrow head in magnified
image). (C) The M71 coding sequence missing a stop codon (pink box) was cloned followed by a linker sequence (yellow box) and the coding sequence of
GFP (green box). The peGFP-N1 backbone includes the cytomegalovirus promoter (CMV, arrow), a 5’ untranslated region (5’UTR, blue box) and a
polyadenylation sequence (pA, black box). The resulting 2D structure of the fusion protein is showed, the M71 odorant receptor has a putative 7
transmembrane domains structure and is glycosylated at its N-terminus (pink diagram). The GFP protein, composed of eleven β-barrels, is fused to the Ct of
M71 (green diagram) after a 9 amino acids linker (in yellow). M71::GFP shows intense perinuclear localization in an OP6 cell (see picture) and does not
localize to filopodia. (D) Using the same strategy the mβ2AR sequence (teal box) was cloned in the same backbone. mβ2AR has also 7 transmembrane
domains but 2 N-linked glycosylation sites located in its Nt (see 2D topology). When express in OP6 cells (see picture) mβ2AR::GFP stains homogeneously
the whole cell and locates in filopodia (arrow head in magnified image), like gap::GFP. (E) Cells expressing GFP and M71::GFP have very low number of
GFP-labeled filopodia (gray bars, 2.8 ±2.9 and 0.0 ±0.0 GFP-labeled filopodia per cell respectively), whereas cells expressing gap::GFP and mβ2AR::GFP
show the same numerous number of filopodia. In addition many cells expressing GFP and M71::GFP show1 GFP-labeled filopodium whereas all cells
expressing gap::GFP or mβ2AR::GFP have more filopodia (blue diamonds, 2nd y axis in graph). (F) Counts of GFP- and CellMask Deep Red-labeled
filopodia for cells expressing GFP or gap::GFP. The number of filopodia revealed by plasmamembrane staining is the same for both type of cells (44.7 ±15.9
and 33.6 ±9.9 respectively), only in cells expressing gap::GFP-filopodia are also GFP-labeled (orange bars in graph, 2.6 ±3.2 and 33.2 ±9.8 co-labeled
filopodia per cell respectively). All filopodia counts are represented as average for 10 cells ± standard deviation. ***means significantly different from
mβ2AR::GFP, one-way ANOVA followed by Scheffe tests, p<0.001. n.s. means not significantly different frommβ2AR::GFP, p>0.001.
doi:10.1371/journal.pone.0141696.g002
In VitroMutational Analysis of the β2 Adrenergic Receptor
PLOS ONE | DOI:10.1371/journal.pone.0141696 October 29, 2015 6 / 28
or gap::GFP were comparable (p>0.001, ANOVA followed by the post hoc Scheffe tests, Fig
2F). Thus, filopodia localization of membrane targeted and fluorescently tagged proteins pro-
vides a suitable assay for plasma membrane localization in OP6 cells. Additionally, the measure
of OP6 cells with1 GFP-labeled filopodia (blue diamonds) proves to be inversely correlated
to the average number of GFP-labeled filopodia.
Differential plasma membrane trafficking for M71::GFP and mβ2AR::
GFP
What is the cellular fate of ORs fused to a Ct GFP tag (OR::GFP) and expressed in OP6 cells? To
answer this question, we chose the M71 OR gene (olfr151) since it has been well studied in vivo
in gene-targeted and transgenic mice where M71::GFP traffics and responds to M71 specific
odors in olfactory neurons ([7, 11]). M71::GFP expression in OP6 cells is observed perinuclearly
(Fig 2C and 2E), which recapitulates the failed expression patterns observed for most ORs heter-
ologously expressed in other cell types. Importantly, the filopodia are present, but M71::GFP
cannot traffic to them. Filopodia are readily identified by CellMask in M71::GFP expressing OP6
cells comparable to the number of filopodia observed for GFP or gap::GFP (p>0.001, [11]).
Fusion of GFP to the Ct of mβ2AR, mβ2AR::GFP, reveals homogenous fluorescence
throughout the whole cell including the filopodia, in the same manner as gap::GFP (Fig 2D vs.
2B). All cells robustly show GFP-labeled filopodia (Fig 2E) comparable to gap::GFP (p>0.001).
Plasma membrane labeling with CellMask of OP6 cells expressing mβ2AR::GFP reveals that all
25.3 ±16.3 red filopodia per cell are double labeled with GFP fluorescence ([11]), which is simi-
lar to the number of CellMask labeled filopodia observed in cells expressing GFP, gap::GFP
and M71::GFP (44.7 ±15.9, 33.6 ±9.9 and 34.3 ±14.4 respectively, p>0.001; Fig 2F and [11]).
This analysis suggests that the number of filopodia in OP6 cells does not depend on the
expressed protein, plasma membrane-associated (gap::GFP or mβ2AR::GFP) or otherwise
(GFP or M71::GFP).
We have previously shown that the addition of fluorescent tags at the Ct of the mβ2AR does
not inhibit trafficking of mβ2AR to the plasma membrane nor impair the functional response
after ligand stimulation with isoprenaline, a known mβ2AR agonist [14]. Thus, we were in a
position to quickly screen for proper trafficking of mβ2AR::GFP mutants by examining the
presence of GFP-labeled filopodia and correlate this with isoprenaline-induced activation.
N-terminal and C-terminal truncations of mβ2AR still traffic to the plasma
membrane
We first sought to understand why the mβ2AR protein robustly traffics to the plasma mem-
brane and the M71 OR protein does not. Using the crystal structure of human β2AR as a tem-
plate, we set out to dissect the mβ2AR primary sequence and determine what changes could
inhibit plasma membrane trafficking and/or function to the protein (Fig 1A and 1B). When
compared to mβ2AR, the M71 OR has a shorter Nt (Nt: 28 vs. 34 amino acids, respectively),
contains only one N-linked glycosylation site and has a much shorter Ct (Ct; 18 vs. 89 amino
acids, respectively) not subject to palmitoylation. Our initial step to determine why mβ2AR
traffics to the plasma membrane was to systematically reduce its primary sequence to that of
the non-trafficking odorant receptor M71.
First, we internally deleted the Nt of mβ2AR to be a similar length to M71, with only one N-
linked glycosylation site. This 9 residues deletion, inside the Nt of mβ2AR (NtΔ9AA; green cir-
cles in 2D topology of the protein in Fig 1B), includes one of the glycosylation consensus
sequences NxS. We observed normal trafficking and maximum responses to isoprenaline and
the half maximal effective concentration (EC50) for NtΔ9AA comparable to WT (i.e. mβ2AR::
In VitroMutational Analysis of the β2 Adrenergic Receptor
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GFP, Fig 3F and yellow curve in Fig 3E). This indicates that a shorter N-terminus with only
one N-linked glycosylation site does not affect affinity of this receptor to isoprenaline or down-
stream ligand-induced signal transduction.
We had previously shown that the truncation of the full Ct of mβ2AR, up to and including
arginine 328 (ΔCt➔R328; Fig 1B), prevents its trafficking to filopodia and response to isopren-
aline [14]. Here, we also observe accumulation of the protein ΔCt➔R328 in the cytoplasm of
the cells and no localization in filopodia (Fig 3B and 3F). The lack of response to isoprenaline
of ΔCt➔R328 is either due to the protein not targeting to the plasma membrane, not folding
properly on the way to the plasma membrane, or very low levels of protein on the plasma
membrane (Fig 3E). Thus, it seemed likely that properties within the Ct are necessary for
mβ2AR::GFP efficient trafficking to the plasma membrane and isoprenaline-mediated
activation.
Can mβ2AR traffic and function with a short Ct? We truncated the Ct of mβ2AR up to and
including residue tyrosine 350 (ΔCt➔Y350, Fig 1B), so that it contains a Ct with the same
length as the M71 Ct. Plasma membrane trafficking for ΔCt➔Y350 is comparable to WT (Fig
3F). However, this Ct mutant possesses a log higher EC50 (Fig 3F) and a lower maximum
response (70% of WT, Fig 3E and 3F).
Next, we truncated both the Nt and Ct of the receptor (NtΔ9AA/ΔCt➔Y350), resulting in a
mβ2AR mutant with the same approximate length as M71 (341 amino acids instead of 418; -9
at Nt and -68 at Ct). Again, this fusion protein retained the capacity to traffic to filopodia (Fig
3F) and the same response profile to isoprenaline as ΔCt➔Y350 (table in Fig 3E and 3F).
Within the Ct of the human β2AR, palmitic acid was shown to bind a cysteine residue at
position 341 [19]. Residue C341 is conserved in the mouse β2AR Ct (Fig 1B) but it is absent in
the Ct of the non-trafficking M71 OR. Therefore, we deleted C341 in mβ2AR. The resulting
mutant NtΔ9AA/ ΔCt➔Y350/ΔC341 shows normal plasma membrane trafficking and the
anticipated reduced EC50 due to the ΔCt➔Y350 mutation (Fig 3C, 3E and 3F). These results
show that a mutated mβ2AR that is similar in length and character to an OR, i.e., with shorter
Nt and Ct, one N-linked glycosylation site in its Nt and no palmitoylation site, is still able to
traffic to the plasma membrane and that these features are not essential for GPCR trafficking
to the plasma membrane.
mβ2AR N-linked glycosylation sites are not required for functionality
The NxS/T consensus sequence marks proteins for asparagine (N)-linked glycosylation. Multi-
ple N-glycosylation sites at the Nt of GPCRs are common and thought to be involved in plasma
membrane trafficking, but its role may vary among GPCRs [20]. To further explore the role of
N-linked glycosylation in the Nt of mβ2AR, we mutated the only two N-linked glycosylation
sites present on the extracellular domain of the entire full-length protein. We replaced the
asparagine of NDS and NGS with alanine (N6A and N15A) to create no-NxS (Fig 1B). Surpris-
ingly, this mutant showed a similar expression pattern to WT (Fig 3D).
Interestingly, the no-NxS mutant shows an increased response to isoprenaline (Maximum
response is 120% of the mβ2AR::GFP response, Fig 3E and 3F) with an EC50 for isoprenaline
similar to WT (0.67nM vs. 0.42nM, respectively). This suggests that the lack of Nt N-linked
glycosylations in a GPCR leads to an enhanced capacity to transduce a signal in response to its
ligand but is not essential for trafficking to the plasma membrane.
Membrane localization and function of β2AR Activity Mutants
Our experiments have revealed three phenotypes: 1) membrane trafficking with EC50s similar
to WT 2) membrane trafficking with higher EC50s and 3) non-membrane trafficking with
In VitroMutational Analysis of the β2 Adrenergic Receptor
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absent EC50s. We sought to explore if previously characterized activity mutants of human
β2AR, which had been expressed in olfactory neurons and shown to provide axons with a dif-
ferent identity compared to human β2AR [8], might reveal a new phenotype in our assay: one
with a loss-of-function mutation (RDY) and two mutations associated with increased basal
Fig 3. Reducing mouse β2AR primary sequence to that of the odorant receptor M71. (A) mβ2AR::GFP showing homogenous and sharp edges staining
of OP6 cells (observed in 10/10 cells), is included in small isolated inclusions and also locates to filopodia (arrow head in magnified picture). (B) On the
contrary, ΔCt➔R328 shows accumulation around the nucleus and does not locate to filopodia (9/10 cells, magnified picture). (C) The mutated final version of
mβ2AR that looks like an OR, NtΔ9AA/ΔCt➔Y350/ΔC341, shows similar localization in OP6 cells as WT, including in filopodia (arrow head in magnified
picture). (D) In the same way No-NxS shows proper trafficking in OP6 cells. (E) Dose response curves obtained by the degree of isoprenaline-induction in
FLIPR experiments, are depicted as normalized relative fluorescent units (RFUs) as a function of Log [isoprenaline] (M, molar concentration). The same color
code is used as in F. (F) The average number of GFP-labeled filopodia per cell is showed (bars in graph, mean +s.d.) as well as the number of cells with1
GFP-labeled filopodia (blue diamonds). WT labels 31.8 ±16.2 filopodia per cell, ΔCt➔R328 0.5 ±1.6***, NtΔ9AA 24.3 ±10.2n.s., ΔCt➔Y350 28.0 ±14.4n.s.,
NtΔ9AA/ΔCt➔Y350 17.3 ±6.9n.s., NtΔ9AA/ΔCt➔Y350/ΔC341 15.0 ±8.8n.s., and No-NxS 13.6 ±8.3n.s.. ***means significantly different fromWT, one-way
ANOVA 8 degrees of freedom followed by Scheffe tests, p<0.001. n.s. means not significantly different fromWT, p>0.001. EC50 (nM) and maximum
response (expressed as a % of mβ2AR::GFP’s maximum response) for isoprenaline are indicated in the table. N/A indicates not applicable, EC50 and
maximum response cannot be calculated if the mutant shows no activity in response to isoprenaline and no dose response curve can be fitted, as it is the
case here for ΔCt➔R328.
doi:10.1371/journal.pone.0141696.g003
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activity (E268A and C327R). We postulate that differences in their ability to traffic to the
plasma membrane might also account for shown differences in axonal identity.
A highly conserved region aspartic acid-asparagine (DRY) suspected to be involved in G-
protein coupling has been previously mutated to asparagine-aspartic acid (RDY) in the rat I7
(rI7) OR and was non-functional. Neurons expressing rI7(RDY) do not show Ca2+ signals in
response to its cognate ligand, octanal, and their axons fail to develop normal connections [21,
22]. Like many other ORs, the rI7(RDY) protein is unlikely to traffic to the plasma membrane
in heterologous cells [23] and its trafficking has not been analyzed in olfactory neurons. Thus,
loss-of-function in signaling and axonal phenotypes for the RDY mutant could also be
explained by a loss of membrane trafficking. In order to analyze the effect of the RDY mutation
on plasma membrane trafficking we generated the same mutations in the conserved region in
both mouse and human β2AR (Fig 1B). Surprisingly, we observe isoprenaline responses for
both mouse and human RDY mutants (Fig 4E, 4F, 4J and 4K), with a maximum response rate
of ~60% when compared to WT for both mutants. However, their EC50s are two-fold higher
when compared to their WT counterparts. Both mouse and human RDYmutants traffic poorly
to the plasma membrane and GFP-labeled filopodia are significantly lower in number. The
human RDY mutant shows some accumulation in the periphery of the nucleus (Fig 4B),
whereas the mouse RDY mutant accumulates protein in punctate inclusions within the cells
and shows relatively poor expression in the rest of the cell (Fig 4G). In summary, our results
reveal that the RDY mutation impairs both ligand-induced activity and plasma membrane traf-
ficking for the β2AR.
In olfactory neurons, co-expression (using an Internal Ribosome Entry Site or IRES
sequence) of a constitutively active form of a G-protein (caGs), together with rI7(RDY), rescues
some of the receptor function in axonal guidance [21]. Since G-proteins are known associates
of GPCRs, it is possible that caGs enhance trafficking of an RDY mutant. This prompted us to
determine if the filopodia localization of the mouse RDY mutant is affected when co-expressed
with caGs (mouse RDY/IREScaGs). Co-expression of caGs did not rescue plasma membrane
trafficking of mouse RDY (Fig 4K). This suggests that the rescue of the axonal targeting pheno-
type observed in vivo for rI7(RDY)-IRES-caGs is not due to a change in plasma membrane traf-
ficking of the receptor.
Subsequently, we tested two mutations with increased basal activity (E268A and C327R; Fig
1B) in both human and mouse β2AR. The charge-neutralizing mutation E268A has been previ-
ously described to increase both basal and induced activity of hβ2AR (increase of cyclic AMP
accumulation in transiently transfected COS-7 cells) [24]. In addition, the mutation reduced
the expression level in cells, possibly due to an increased instability of the protein [24]. In our
paradigm, we did not observe an increase of response to isoprenaline for both the human and
the mouse E268A mutant. On the contrary, the maximal isoprenaline responses for both are
reduced (Mouse: Fig 4E and 4F, Human: Fig 4J and 4K), but their respective EC50s are similar
to their WT counterparts (Fig 4F and 4K). Strangely, the plasma membrane trafficking of
mouse E268A appears normal (Fig 4H and 4K) whereas the human E268A fails to traffic prop-
erly to filopodia (Fig 4C and 4F). This is consistent with data from Ballesteros et al. [24] sug-
gesting a reduced level of expression of the human activity mutant. We conclude that the
E268A mutation is a partial loss-of-function mutant rather than a gain-of-function, as was pre-
viously described.
Thereafter, we analyzed the plasma membrane expression for the C327R mutation in both
the human and mouse β2AR (Fig 1B), which was previously described to reduce the binding
affinity of hβ2AR for isoprenaline and the efficacy of the receptor to stimulate adenylyl cyclase
[25]. We confirm that both human C327R and mouse C327R mutants show much higher
EC50s to isoprenaline (87.31nM and 20.97nM, respectively) and decreased maximum
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Fig 4. Plasmamembrane trafficking of human andmouse β2ARmutants for activity. (A) The human version of β2AR::GFP shows an homogenous
staining in OP6 cells, similar in localization to mβ2AR::GFP, but more faint (observed in 10/10 cells). The protein also locates to small isolated inclusions and
filopodia (arrow head in magnified picture), also at a lower level than mβ2AR::GFP. In this figure all zoom-in pictures are corrected for contrast to allow good
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responses (35% and 58%, respectively) when compared to their WT counterparts (Fig 4E, 4F,
4J and 4K). Unlike RDY mutations and the mouse E268A mutation, both the human and
mouse C327R mutants traffic well to the plasma membrane (Fig 4D, 4F, 4I and 4K).
Examination of these three altered-function activity mutants reveals two additional pheno-
types: 1) membrane trafficking with1 log higher EC50s and 2) poor membrane trafficking
with1 log higher EC50s. Moreover, the human and mouse β2ARs appear to be differentially
affected in their trafficking for the same mutation.
Aminimal C-terminus sequence requirement for mβ2AR
In order to determine the critical role of the Ct for mβ2AR plasma membrane trafficking, we
performed a series of C-terminal truncations (Fig 1B). The phenotype of the ΔCt➔R328 muta-
tion that we previously characterized is slightly unexpected as the mβ2AR protein is linked to
the Ct GFP tag via a Ct 9 amino acid linker (LINDPPVAT), both of which could conceivably
replace the 21 amino acids that were deleted between R328 and Y350 (plus ΔC341). Because
ΔC341 did not alter localization of mβ2AR to the plasma membrane we postulate that amino
acids between L340 and R328 are critical. Thus, we stepwise deleted amino acids to create the
mutant series ΔCt➔L340 to ΔCt➔I334. We observe that mutants with a Ct truncated up to
and including leucine 340 (ΔCt➔L340, data not shown), leucine 339 (ΔCt➔L339), glutamic
acid 338 (ΔCt➔E338), and glutamine 337 (ΔCt➔Q337), traffic effectively to filopodia (Fig 5A,
5B and 5F). In contrast, mutants with a truncation up to and including phenylalanine 336
(ΔCt➔F336), alanine 335 (ΔCt➔A335) or isoleucine 334 (ΔCt➔I334), fail to traffic success-
fully to filopodia (Fig 5C, 5D and 5F).
One interpretation of our deletion series is that a Ct tail of 8 amino acids (PDFRIAFQ) is
necessary for the receptor to traffic successfully to filopodia. Normally the Ct associates with
the plasma membrane through the palmitoylation of the C341 residue. Thus, the 13 residues
from 328 to 341 might have a specific hydrophobic character to allow this event to occur and a
change in this overall hydropathic character might explain why different versions of the Ct do
not allow for trafficking. The 8 amino acids sequence PDFRIAFQ has a composite hydropathy
index of -2.0 [26]. Removal of Q337 (the last amino acid needed for trafficking) alters the com-
posite hydropathy index to a net positive of 1.5. The 9 amino acids, LINDPPVAT, in the GFP-
linker sequence also have a net positive composite hydropathy index of 3.4 and perhaps it
explains why it does not substitute. However, the change in charge cannot be the sole reason
display of filopodia. (B) On the contrary, the activity mutant human RDY shows accumulation in the periphery of the nucleus and locate in fewer filopodia (7/
10 cells, arrow head in magnified picture). (C) The human E268A protein shows uniform and faint staining of the cell in addition to small inclusions, but rarely
locates to filopodia (only in 3/10 cells, arrow head in magnified picture). (D) Human C327R shows similar localization than humanWT and locates to filopodia
(10/10 cells, arrow head in magnified picture). (E) Dose response curves to isoprenaline obtained by FLIPR analysis, are showed as normalized relative
fluorescent units (RFUs) as a function of Log [isoprenaline] (M). The same color code is used as in F. (F) The average number of GFP-labeled filopodia per
cell is showed (bars in graph, mean +s.d.) as well as the number of cells with1 GFP-labeled filopodia (blue diamonds). HumanWT labels 25.0 ±10.7
filopodia per cell, human RDY only 2.8 ±1.7***, human E268A 3.4 ±7.3*** and human C327R 15.9 ±9.7n.s.. ***means significantly different from hβ2AR::
GFP, one-way ANOVA 3 degrees of freedom followed by Scheffe tests, p<0.001. n.s. means not significantly different from hβ2AR::GFP, p>0.001. EC50
(nM) and maximum response (expressed as a % of hβ2AR::GFP’s maximum response) for isoprenaline are indicated in the table. (G) As the human version,
mouse RDY shows normal localization inside the cell (8/10 cells) but traffic to only few filopodia (arrow head in magnified picture). (H) However, mouse
E268A does not behave like human E268A, it shows normal localization inside the cell (10/10 cells) and in filopodia (arrow head in magnified picture). (I)
Mouse C327R, as the human version and asWT, shows homogenous staining of the cell and few inclusions (10/10 cells) and locates to filopodia (arrow head
in magnified picture). (J) Dose response curves to isoprenaline obtained by FLIPR analysis, are showed as normalized relative fluorescent units (RFUs) as a
function of Log [isoprenaline] (M). The same color code is used as in K. (K) The average number of GFP-labeled filopodia per cell is showed (bars in graph,
mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue diamonds). MouseWT labels 31.8 ±16.2 filopodia per cell, mouse RDY 9.0
±6.7***, mouse RDY/IREScaGs 3.5 ±5.5***, mouse E268A 18.7 ±9.0n.s. and mouse C327R 23.8 ±9.5n.s.. ***means significantly different fromWT, one-
way ANOVA 4 degrees of freedom followed by Scheffe tests, p<0.001. n.s. means not significantly different fromWT, p>0.001. EC50 (nM) and maximum
response (expressed as a % of mβ2AR::GFP’s maximum response) for isoprenaline are indicated in the table. Mouse RDY/IREScaGs was not tested for
activity.
doi:10.1371/journal.pone.0141696.g004
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Fig 5. Minimal Ct requirements for mouse β2AR plasmamembrane trafficking and activity. (A and B) Truncation of the Ct of mβ2AR to E338 and Q337
does not impair proper trafficking of the protein in the cell (both 10/10 cells) and ΔCt➔E338 and ΔCt➔Q337 successfully traffics to filopodia in both cases
(arrow head in magnified pictures). (C and D) On the contrary, truncated proteins to F336 and A335 show accumulation at the margin of the nucleus and very
rarely locate to filopodia (arrow head in magnified pictures). (E) Dose response curves to isoprenaline obtained by FLIPR analysis, are showed as normalized
relative fluorescent units (RFUs) as a function of Log [isoprenaline] (M). The same color code is used as in F. (F) The average number of GFP-labeled
filopodia per cell is showed (bars in graph, mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue diamonds). ΔCt➔L339 labels 9.0
±4.9n.s. filopodia per cell, ΔCt➔E338 12.2 ±7.9 n.s., ΔCt➔Q337 14.3 ±10.2 n.s., ΔCt➔F336 6.0 ±5.7***, ΔCt➔A335 13.5 ±10.1*** and ΔCt➔I334 0.0
±0.0***. ***means significantly different fromWT, one-way ANOVA 6 degrees of freedom followed by Scheffe tests, p<0.001. n.s. means not significantly
different fromWT, p>0.001. EC50 (nM) and maximum response (expressed as a % of mβ2AR::GFP’s maximum response) for isoprenaline are indicated in
the table. (G) Snake plot of the 7th and last transmembrane domain and the Ct of the protein showing the localization of the last residues included in the
truncation series.
doi:10.1371/journal.pone.0141696.g005
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explaining the obstruction of trafficking, as the additional loss of F336 and F336+A335 alter
the hydropathy to a net negative charge of the remaining 8 or 7 residues, but do not rescue
trafficking.
We have previously observed that ΔCt➔R328 fails to traffic and fails to elicit isoprenaline
responses. These two qualities need not be correlated. Indeed, when we test ΔCt truncation
mutants for their responses to isoprenaline, we do not find isoprenaline-mediated responses
for ΔCt➔Q337 (Fig 5E) and ΔCt➔A335 (Fig 5E), despite ΔCt➔Q337 trafficking to filopodia
(see above). The observed membrane trafficking for ΔCt➔L339 and ΔCt➔E338 (Fig 5E) corre-
lates to only small isoprenaline responses (Fig 5F, maximum responses are 27% and 19% of
WT respectively and their EC50s are 2 logs higher than the WT). Thus, the first nine residues
of mβ2AR Ct are needed to initiate even small isoprenaline responses.
Phenotypic rescue of C-terminus requirement
Our ΔCt truncation mutants show that the mβ2AR Ct tail is involved in G-protein coupling.
However, these mutants do not unravel the reason why plasma membrane trafficking fails to
occur in ΔCt➔R328, ΔCt➔I334, ΔCt➔A335, and ΔCt➔F336 (Figs 3B, 3F, 6A and 6F). One
possible explanation is that the protein needs a specific sequence motif in the Ct tail for proper
folding, but the fusion protein still has a cytoplasmic tail from the linker and GFP tag and their
sequences are not markedly different from those of mβ2AR. Another possibility is that the
mβ2AR protein contains a retention signal sequence that is usually masked by the Ct tail [27].
We therefore looked for a conserved motif near the mβ2AR Ct that might act as a retention
sequence. At the end of the last trans-membrane domain of mβ2AR is a highly conserved
NPxxY region (NPLIY, Figs 1A and 6G). This region, highly conserved throughout the GPCR
superfamily, was shown to be involved in internalization of several GPCRs to the endosomes
[20]. Alanine scanning mutagenesis of the three conserved residues reveal that only the isolated
substitution of Y326A alters trafficking of the protein to the membrane without the presence of
a C-terminus (Neither APLIY, NALIY, nor AALIA can rescue the non-trafficking phenotype).
The Y326A/ΔCt➔R328 mutant shows expression similar to mouse WT (Fig 6B and 6F). Inter-
estingly, both ΔCt➔R328 and Y326A/ΔCt➔R328 show no capacity to signal after isoprenaline
exposure (Fig 6E, comparable to no plasmid-mock transfection). Thus, we have revealed a
major role of the tyrosine residue in the context of the conserved region NPxxY as a retention
signal, if exposed, and we describe a new loss-of-function mutant Y326A/ΔCt➔R328, which
retains normal plasma membrane trafficking.
Y326A rescue is dependent on N-terminal amino acids
We previously observed subtle differences in trafficking and maximum isoprenaline responses
when Nt residues are modified (Fig 3). It is plausible that the Ct truncation mutation that does
not G-protein couple, Y326A/ΔCt➔R328, might also have its plasma membrane trafficking
affected by Nt modifications. A shorter Nt with a single N-linked glycosylation site, NtΔ9AA/
Y326A/ΔCt➔R328, retains normal trafficking (Fig 6F and S1A Fig). Surprisingly, we do not
observe trafficking when both N-linked glycosylation sites are mutated (no-NxS/Y326A/
ΔCt➔R328, Fig 6C and 6F) nor when the Nt is replaced by the Nt of M71 (M71-Nt/Y326A/
ΔCt➔R328, Fig 6D and 6F). All mutants with ΔCt➔R328 are not induced by isoprenaline (Fig
6E and 6F, comparable to mock). The latter two mutants suggest a synergistic interaction
between the Nt of the protein and the Y326A mutation near the Ct of the protein. In addition,
we reveal a glycosylation dependent plasma membrane trafficking phenotype. Curiously, the
M71-Nt completely abolishes all signs of membrane trafficking in almost all fluorescent cells.
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Fig 6. A new loss-of-functionmutants for activity which retains trafficking. (A) A complete deletion of the Ct of mβ2AR to R328 blocks proper trafficking
of the protein, which appears to be retained in the periphery of the nucleus (ΔCt➔R328, 9/10 cells) and does not traffic to filopodia (magnified pictures). (B)
The mutation Y326A rescues trafficking of the protein in the cell (Y326A/ΔCt➔R328, 10/10 cells) and to filopodia (arrow head in magnified pictures). (C and
D) This rescue is not observed anymore when the 2 N-linked glycosylation sites located in the Nt are invalidated (no NxS / Y326A/ΔCt➔R328) or when the Nt
is replaced by the one of M71 (M71 Nt / Y326A/ΔCt➔R328) (respectively 3/10 cells and 8/10 cells). In both cases the protein fails to traffic to filopodia
(magnified pictures). (E) Dose response curves to isoprenaline obtained by FLIPR analysis are showed as normalized relative fluorescent units (RFUs) as a
function of Log [isoprenaline] (M). The same color code is used as in F. (F) The average number of GFP-labeled filopodia per cell is showed (bars in graph,
mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue diamonds). ΔCt➔R328 labels only 0.5 ±1.6*** filopodia per cell, whereas
Y326A/ΔCt➔R328 26.4 ±15.2 n.s., NtΔ9AA/Y326A/ΔCt➔R328 14.7 ±9.5 n.s., no NxS / Y326A/ΔCt➔R328 4.2 ±4.0***, M71 Nt / Y326A/ΔCt➔R328 0.5
±1.1*** and Y326A 14.9 ±7.3 n.s.. ***means significantly different fromWT, one-way ANOVA 6 degrees of freedom followed by Scheffe tests, p<0.001. n.s.
means not significantly different fromWT, p>0.001. EC50 (nM) and maximum response (expressed as a % of mβ2AR::GFP’s maximum response) for
isoprenaline are indicated in the table. (G) Snake plot of the 7th and last transmembrane domain and the Ct of the protein showing the localization of the
NPxxY region as well as R328.
doi:10.1371/journal.pone.0141696.g006
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Thus, the Nt and Ct interactions may play a bigger role in membrane trafficking than previ-
ously considered.
Finally, we determined if the Y326A mutation has an effect on the full length mβ2AR::GFP
protein. We show that Y326A does not affect trafficking (Fig 6F and S2B Fig), but slightly
reduces the maximal response to isoprenaline (89% of the mouse WT) and increases the EC50
by one log (Fig 6E and 6F). Therefore, the residue Y326 may have a role in the G-protein cou-
pling mechanism.
Synergistic action between the Nt and Ct of mβ2AR
Our mβ2AR, modified to resemble the non-trafficking receptor M71, NtΔ9AA/ΔCt➔Y350/
ΔC341, retains the capacity to traffic to filopodia, albeit with reduced activity. This result indi-
cates that it is not simply the length of the Nt and the Ct of the M71 OR that prevents its
plasma membrane expression. Both no-NxS/Y326A/ΔCt➔R328 and M71-Nt/Y326A/
ΔCt➔R328 mutants suggest that a synergistic interaction is occurring between the two ends of
the mβ2AR molecule. We wanted to ask if there could be a synergistic action between the
M71-Nt and M71-Ct. Therefore, we swapped the Nt and Ct of the mβ2AR with those of M71.
The residues of M71-Nt to swap were defined through alignment with the shorter Nt of
mβ2AR, NtΔ9AA, and the residues of M71-Ct to swap were defined through alignment with
the shorter Ct version of mβ2AR, ΔCt➔Y350 (see alignments in Fig 6G). The M71-Nt/mβ2AR
chimera successfully traffics to filopodia (Fig 7B and 7F) with maximal response and EC50 to
isoprenaline comparable to WT as well (Fig 7E and 7F). We have shown that a short Ct tail,
ΔCt➔Y350, is non-restrictive for proper trafficking of the receptor to the plasma membrane.
When we analyze the mβ2AR/M71-Ct chimera, the resulting mutant appears to traffic effi-
ciently to the plasma membrane (Fig 7A and 7F), but its maximum response to isoprenaline is
only 47% of WT and its EC50 is one log higher (Fig 7E and 7F). Therefore, neither the Nt nor
Ct of M71 on their own can account for the failure of M71 to traffic to the plasma membrane
in heterologous cells. However, the addition of the M71-Ct does significantly reduce the
response to isoprenaline, similar to what is observed for NtΔ9AA/ΔCt➔Y350/ΔC341 with
analogous length of the Ct tail and missing its palmitoylation site.
Simultaneous replacement of the Nt and the Ct of mβ2AR with that of M71 reveals a syner-
gistic affect. The M71-Nt/mβ2AR/M71-Ct mutant accumulates in the periphery of the nucleus
(Fig 7C) and fails to traffic to filopodia (Fig 7F). Here, we recapitulate the synergistic effects
observed in M71-Nt/Y326A/ΔCt➔R328 (Fig 6F). Despite M71-Nt/mβ2AR/M71-Ct trafficking
very poorly to the plasma membrane, it maintains a maximum response that is 32% of WT and
its EC50 is 1 log higher thanWT (Fig 7E and 7F). When the M71-Nt is replaced with a shorter
mβ2AR-Nt, resulting in NtΔ9AA/mβ2AR/M71-Ct, the trafficking deficit is corrected, but the
maximal response or EC50 are not (Fig 7D and 7F). This suggests that the negative impact of
M71-Nt together with M71-Ct on the same protein is not due to the shortness of the Nt but
rather to some specific aspect of the M71 sequence. In addition, the maximal responses and
EC50s in the context of three different mβ2AR/M71-Ct mutants do not correlate with the level
of plasma membrane expression, but rather with the presence of the M71-Ct residues. These
results suggest that, in our assays, very little protein is necessary at the plasma membrane to
produce isoprenaline responses similar to mβ2AR mutants that show robust trafficking to the
plasma membrane.
Intra-molecule interactions required for Nt and Ct synergistic effects
To distinguish between an intramolecular Nt and Ct interaction and an intermolecular interac-
tion between the Nt and Ct from different molecules of mβ2ARs, we tested if the observed
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Fig 7. The N- and C- termini of the odorant receptor M71 impair trafficking. (A and B) The replacement of either the Ct or the Nt of mβ2AR with the one of
M71 does not block proper trafficking of the protein inside the cell (both 10/10 cells) and to filopodia (arrow head in magnified pictures). (C) On the contrary
the double swaps of both the Nt and Ct of mβ2AR with the Nt and Ct of M71 blocks proper trafficking of the protein, which accumulates in the periphery of the
nucleus (9/10 cells) and does not locate to filopodia (magnified pictures). (D) This is not observed for a mutant with a shorter Nt and the Ct of M71 (10/10
cells) and the protein successfully traffics to the filopodia (arrow head in magnified pictures). (E) Dose response curves to isoprenaline obtained by FLIPR
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trafficking deficits brought on by the presence of M71 Nt and Ct can be recapitulated if located
on two different proteins. We co-transfected cells with the chimeras M71-Nt/mβ2AR::GFP and
mβ2AR/M71-Ct::mCherry. The number of GFP-labeled filopodia observed, is comparable to
both WT and M71-Nt/mβ2AR::GFP expressed alone (Fig 7H and 7J). The results are similar in
the reciprocal co-transfection experiment: mβ2AR/M71-Ct::GFP with M71-Nt/mβ2AR::
mCherry (Fig 7I and 7J). Thus, the Nt and Ct synergistic effects require intra-molecular inter-
actions to block plasma membrane trafficking. This synergistic effect between the Nt and Ct
may partially explain why some GPCRs, like ORs, do not traffic in heterologous cells.
Discussion
A new easy and robust assay for plasma membrane localization of
GPCRs
We have further developed our GPCR expression-profiling assay using C-terminal GFP fusions
for the rapid analysis of mutant GPCR localization throughout the cell without the need for
antibody staining. Our previous analysis of mβ2AR fused to 7 different fluorescent proteins
(XFPs) from four species revealed that mβ2AR::XFPs traffic to the plasma membrane and
retain functionality equivalent to untagged mβ2AR. In particular, GFP appears to be nearly
inert in fusion proteins [14].
We took advantage of the OP6 cell morphology, as they have abundant filopodia where
GFP does not traffic unless fused to a plasma membrane protein. We observed an average of
34.5 ±15.4 filopodia (observed by CellMask staining) per OP6 cell expressing either GFP, gap::
GFP, mβ2AR::GFP or M71::GFP. The number of filopodia is therefore unaffected by the type
of protein expressed in this study. Quantification of GFP-labeled filopodia is an easy and robust
method to test for plasma membrane localization.
Even though epitope identification can be advantageous in the detection of very low protein
levels, especially at the plasma membrane, these detection schemes require live-cell antibody
staining [28], without cell permeabilization, so that only the protein present at the plasma mem-
brane can be bound by the antibody. This antibody assay reveals only a partial view of protein
trafficking within the cell. For instance, some studies of non-trafficking ORs show live-cell anti-
body staining at the membrane, which is marginal compared to the preponderance of the protein
stuck inside the cell when revealed after permeabilization [29]. Moreover an antibody recogniz-
ing an extracellular epitope is needed, restricting the number of GPCRmutants that can be ana-
lyzed. When such antibodies are not available, which is most of the time, tags (FLAG, RHO, HA
and LUCY) are often added to the Nt of the recombinant protein [4]. On the contrary, fluores-
cent protein fusions can be added to the Ct of any GPCR or mutant of interest, allowing the
analysis are showed as normalized relative fluorescent units (RFUs) as a function of Log [isoprenaline] (M). The same color code is used as in F. (F) The
average number of GFP-labeled filopodia per cell is showed (bars in graph, mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue
diamonds). M71-Nt/mβ2AR labels 32.1 ±24.2 n.s. filopodia per cell, mβ2AR/M71-Ct 10.3 ±5.2 n.s., M71-Nt/mβ2AR/M71-Ct 1.6 ±5.1*** and NtΔ9AA/mβ2AR/
M71-Ct 13.2 ±11.3 n.s.. ***means significantly different fromWT, one-way ANOVA 6 degrees of freedom followed by Scheffe tests, p<0.001. n.s. means not
significantly different fromWT, p>0.001. EC50 (nM) and maximum response (expressed as a % of mβ2AR::GFP’s maximum response) for isoprenaline are
indicated in the table. (G) Top pair is the alignment between the Nt of M71 and the truncated version of the Nt of mβ2AR (NtΔ9AA) and on the bottom pair is
the alignment between the Ct of M71 and the truncated version of the Ct of mβ2AR (ΔCt➔Y350). Conserved residues are in violet and sequences present in
the chimera are in the red boxes. (H) The chimera M71-Nt/mβ2AR::GFP shows normal localization in cells and localize to filopodia (arrow head in magnified
picture) when co-expressed with mβ2AR/M71-Ct::mCherry. (I) mβ2AR/M71-Ct::GFP also locates as theWT in cell including to filopodia (arrow head in
magnified pictures) when co-expressed with M71-Nt/mβ2AR::mCherry. (J) The average number of GFP-labeled filopodia per cell is showed (bars in graph,
mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue diamonds). M71-Nt/mβ2AR::GFP labels 32.1 ±24.2 n.s. filopodia per cell and
14.8 ±7.3 n.s. when co-expressed with mβ2AR/M71-Ct::mCherry. mβ2AR/M71-Ct::GFP labels 10.3 ±5.2 n.s. filopodia per cell and 10.7 ±9.7 n.s. when co-
expressed with M71-Nt/mβ2AR::mCherry. M71-Nt/mβ2AR/M71-Ct::GFP labels only 1.6 ±5.1*** filopodia per cell and 2.2 ±2.6***when co-expressed with
mβ2AR/M71-Ct::mCherry.
doi:10.1371/journal.pone.0141696.g007
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visualization of both plasma membrane localization as well as any intracellular compartment
localization simultaneously. In addition, we do not use Nt tags assuring that the critical initial
steps of translation, endoplasmic reticulum (ER) trafficking andmembrane insertion, are a repre-
sentation of the cognate amino acids. Ironically, Nt tags such as FLAG, RHO, HA and LUCY are
typically used to improve ER trafficking and protein expression, which is useful for heterologous
cell expression in many studies but would confound our structure-function analysis.
We have efficiently begun to define the characteristics of GPCRs that traffic to the plasma
membrane. Previous studies by others already analyze Ct truncations [30] or chimeric recep-
tors [5, 31] but, in most cases, with Nt-tags. Our analysis deconstructs GPCR trafficking and
G-protein coupling. For the first time this assay allows to easily perform an extensive site-
directed mutagenesis of GPCRs without the use of antibodies.
The dynamic range of our GPCR::GFP-labeled filopodia averages is between 0 and 32.1 per
cell. All average counts above 10 (19/19), readily described a mutant as trafficking to the
plasma membrane. Only one mutant, ΔCt➔L339, appeared to traffic with a GFP-labeled filo-
podia average count less than 10. We also show that 19/20 trafficking mutants do not have any
cells with1 GFP-labeled filopodia. This inverse correlation holds true for 13/13 non-traffick-
ing mutants tested (see blue diamonds in S3 Fig; only NtΔ9AA/Y326A/ΔCt➔R328 breaks this
correlation). All non-trafficking mutants have at least 2/10 cells with1 GFP-labeled filopodia.
Hence, our two measures of GPCR membrane trafficking are highly correlated, reinforcing our
confidence that the number of GFP-labeled filopodia for 10 cells is a sufficient measure for
proper expression of a given GPCR in OP6 cells.
N-linked glycosylations of the Nt and palmitoylation are not essential
features for GPCR trafficking
Our results suggest that N-linked glycosylation sites at the Nt of a GPCR are not necessary for
robust mβ2AR plasma membrane trafficking or G-protein coupling. A previous study has
showed, through a ligand binding assay in COS-7 cells, that only 52% of the hamster N6Q
N15Q β2AR was expressed on the cell surface, compared to 95% of the WT hamster receptor
[32]. In contrast, our study reveals an increase in maximal response to isoprenaline (120% of
the mouse WT) without significant change to the EC50 and trafficking. This different pheno-
type observed could reveal species-specific features of the receptor, as we show for activity
mutants between human and mouse β2AR. Such increased activity for a GPCR glycosylation
mutant has already been described, as the mutated Protease-activated receptor-1 (PAR1) lack-
ing glycosylation of its 2nd extracellular loop showed a greater efficacy in G-protein signaling
[33]. Likewise, the glycosylation status of a protein can be cell-type specific, and our results
could reveal that N-linked glycosylation of the N-terminus of a GPCR is not a necessary feature
for proper trafficking in an olfactory placode-derived cell line or HEK293T cells (used for dose
response curves). We have only characterized N-linked glycosylation mutants with the high-
affinity isoprenaline ligand. It is known that a given GPCR can activate different pathways and
that some ligands activate different subsets of those effectors [34], hence other ligands may
depend on N-linked glycosylation sites to activate mβ2AR. We observe that the addition of var-
ious N-linked glycosylation sites to the N-terminus of the M71 OR, do not rescue protein traf-
ficking to the plasma membrane [11]. Taken together, these results suggest that N-linked
glycosylation at the N-terminus of a GPCR is neither necessary nor sufficient for membrane
trafficking of the protein. This result is rather surprising, as the in vivoM71 OR mutation
N5Q, disrupting its only potential glycosylation site, can no longer promote axon guidance,
but is likely still able to lock in OR gene choice [7]. It will be interesting to see if glycosylation
of mβ2AR is necessary for its ability to act as a surrogate OR in vivo.
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Next, we showed that palmitoylation of mβ2AR is unnecessary for proper trafficking to the
filopodia of OP6 cells. Binding of palmitic acid to cysteine 341 (C341) in the Ct of human
β2AR allows for anchoring of the protein to the membrane. This anchoring seems not impor-
tant for trafficking but rather for G-protein coupling. Indeed deleting C341 lowers the isopren-
aline-induced activity by 5 fold, EC50 of 1.65nM for NtΔ9AA/ΔCt➔Y350 compared to
8.86nM for NtΔ9AA/ΔCt➔Y350/ΔC341. It is possible that signaling pathways using different
G-proteins or β-arrestins have been disrupted as well.
β2AR Activity Mutants have different trafficking phenotypes
The study of OR function in olfactory neurons has been limited due to our inability to test in
vitromutants with possible altered signaling abilities. Human β2AR mutants have been tested
in vivo for their function in axon guidance, but have yet to be carefully characterized in vitro
using isoprenaline-induced signaling and plasma membrane trafficking assays. We reveal that
the RDY (D130R; R131D) mutation shows a drastic effect on protein trafficking for both
human and mouse β2AR. The localization of rI7 RDY mutant in olfactory neurons has never
been analyzed in vivo nor in vitro [21]. In contrast to rI7 RDY activation by octanal, mouse
and human RDY mutants maintain functionality in vitro. Their EC50s are similar to WT and
for both the maximum isoprenaline response is reduced to ~60% (Fig 8). This reduction of the
maximum response is most likely a consequence of poor membrane trafficking. A further anal-
ysis reveals that the D130R substitution alone blocks membrane trafficking whereas the R131D
substitution does not (data not shown). The D130 appears to be a key residue for mouse β2AR
trafficking as the mutation D130N also disrupts this process (data not shown).
The neutralizing E268A mutation has the same effect on both human and mouse β2AR.
They both have the same EC50 as WT (Fig 8) and their maximum responses are both about
50% of the WT. Conversely, the two proteins show different trafficking phenotypes; mouse
E268A retains the capacity to traffic to filopodia (Fig 8) whereas human E268A does not (Fig
8). However, the high sensitivity of the dose response curve assay could not discriminate their
differences in plasma membrane trafficking at a single cell level. Finally, the C327R mutation,
located at the end of the 7th transmembrane domain, does not affect trafficking to filopodia of
both human and mouse β2AR but drastically increases their EC50 for isoprenaline revealing a
reduced G-protein coupling efficiency.
In the olfactory system, GPCRs like ORs and β2AR, provide an axonal identity to olfactory
neurons that is reflected by the coalescence of like-axons into specific neuropils in the olfactory
bulb, called glomeruli [7, 35]. We undertook the analysis of β2AR RDY, C327R and E268A
mutants to better understand the in vivo significance of these mutants when expressed in olfac-
tory neurons and cause differential axonal identities [8]. The original finding argues that axonal
identities vary due to basal and/or ligand-associated activity of the receptor. However, our data
open up a third possibility: differential axon identities are a feature of differential plasma mem-
brane trafficking properties. Indeed we have previously shown that a reduction in protein level
of an OR is a major determinant for its axonal identity [7, 36]. In addition, it is shown that sin-
gle amino acid differences in ORs change axonal identities [35]. Thus, it is impossible to
uncouple mutations such as RDY, C327R and E268A from directly changing the axonal iden-
tity code to their affects on activity and/or receptor trafficking.
Y326 within the conserved NPxxY motif acts as a retention signal
We reveal that mβ2AR with a Ct-truncation up to and including R328 fails to traffic properly
to the plasma membrane, but can be fully rescued by a second mutation Y326A. However, no
rescue of isoprenaline response is observed despite robust plasma membrane expression.
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Unlike RDY, E268A and C327R where all retain some level of isoprenaline-inducible activity,
our new loss-of-function mutant (Y326A/ΔCt➔R328) provides an excellent tool to study activ-
ity-independent axon guidance in the olfactory system: it traffics properly to the plasma mem-
brane but fully fails to transduce a signal.
We have not characterized what other substitutions of Y326 can rescue the ΔCt➔R328
mutant. However, we have observed that an alanine (A) substitution of all three conserved resi-
dues (AAxxA) does not rescue trafficking, thus makes unclear whether there is a structural
property and/or a modification of Y326 that occurs in the absence of the Ct.
The NPxxY motif is highly conserved among many GPCRs, and perhaps a mutation in its
tyrosine residue might improve plasma membrane trafficking of other non-trafficking GPCRs.
However, this improvement in trafficking may also cause a reduction in activity as the Y326A
mutation increases isoprenaline-induced EC50 within the intact mβ2AR (Fig 8).
Fig 8. Plot for relative EC50 and% of maximum response. All mutants are positioned for their relative EC50 for isoprenaline (EC50/EC50 of WT) on the y-
axis (log scale) and their maximum response as a % of WT on the x-axis. Mutants that fail to traffic to the plasmamembrane are depicted as red diamonds
and mutants that properly traffic to the plasmamembrane are depicted as green diamonds. The red box indicates all the mutants with a lower affinity for
isoprenaline thanWT i.e. EC50/EC50 of WT >>1 (from 3.9 to 77.4). All these mutants have mutations in the last 7th transmembrane domain or the Ct of the
protein. The black box includes all the mutants that have a similar affinity for isoprenaline than WT i.e. EC50/EC50 of β2AR::GFP 1 (from 0.8 to 2.1).
doi:10.1371/journal.pone.0141696.g008
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We have tested the effect of altering the NPxxY motif to NPxxA on the non-trafficking M71
OR, with the hypothesis that the Ct of M71 fails to mask the retention thus blocking proper
trafficking of the receptor. However, no plasma membrane trafficking was observed in M71
mutants carrying Y289A [11].
N- and C-termini of a non-trafficking GPCR impair β2AR trafficking
The study of chimeras between mβ2AR and the non-trafficking M71 OR, reveals the negative
synergistic effects of the Nt and Ct of M71 on plasma membrane trafficking. The presence of
either the Nt or the Ct alone does not impair plasma membrane trafficking of the chimera,
indicating that these domains do not modify the secondary structure of the protein. Since it is
the Nt and Ct domains on the same protein, which are deleterious for protein trafficking, it is
likely that proper protein folding into a seven transmembrane (7TM) structure is dependent
on an appropriate interaction between the Nt and Ct of the protein. This is consistent with the
proximal relationship between transmembrane domain one (TM1) and TM7 in the 7TM struc-
ture and may be a critical feature for how GPCRs normally achieve this confirmation. Con-
versely, TM1 and TM7 are brought together to form the final tertiary structure by specific
chaperones.
Perhaps the Nt and Ct of M71 block the formation of the 7TM structure when M71 is
expressed in heterologous cells. Thus, we swapped the Nt and Ct of M71 with those of mβ2AR,
generating mβ2AR-Nt/M71/mβ2AR-Ct. This mutant does not traffic to the filopodia of OP6
cells [11]. In addition, the inclusion of the Y289A mutation does not rescue plasma membrane
trafficking either [11]. Indeed, our extensive mutant analysis on M71 OR [11] suggested that
plasma membrane trafficking of ORs involves a more distributed involvement of the amino
acid composition.
In addition, when co-expressing our mβ2AR mutants with the receptor-transporting pro-
tein 1S (RTP1S), which is known to improve plasma membrane trafficking of various odorant
receptors [37], we do not reveal any significant difference in plasma membrane trafficking for
WT mβ2AR::GFP or 17 of our mutants (see pictures and filopodia counts in S4 Fig). Impor-
tantly, no rescue is observed for mβ2AR chimeras with M71 Nt and/or Ct. However, several Ct
deletion mutants show fewer cells with1 GFP-labeled filopodium. This suggests that the role
of RTP1S in improving plasma membrane trafficking is not related to the Nt and Ct interaction
that we observe.
Relationship between trafficking and activity
We observed that mβ2AR::GFP EC50s and maximum responses are relatively refractory to
changes in DNA transfected (i.e. a 32 fold reduction is still able to elicit near WT levels; data
not shown). These results suggest that changes in EC50 and maximum responses observed in
our mβ2AR mutants are solely a function of their trafficking and/or coupling phenotypes. We
find that the mβ2AR mutant responses to isoprenaline did not fully correlate with successful
trafficking observed for seventeen mutants. Three mutants fail to respond and eleven show a
lower maximum response thanWT, as low as 20% (black diamonds and green bars in S5 Fig).
Hence, even though several mutants traffic effectively to the plasma membrane, they show
defects in eliciting responses to isoprenaline.
In contrast, none of the mutants that fail to traffic to the plasma membrane show a maxi-
mum response greater than 60% and most of them, six out of ten, fail to respond (red dia-
monds and red bars in S5 Fig). Overall, only three mutants that successfully traffic to the
plasma membrane show similar (2 blue diamonds) or superior (1 violet diamond) maximum
response to isoprenaline when compared to WT. Maximum isoprenaline responses for our
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mutants as high as WT cannot be achieved without successful trafficking. This correlation
between filopodia trafficking in OP6 cells and response to isoprenaline in HEK 293 cells indi-
cates that the filopodia assay in OP6 cells is a robust tool to study receptor functionality.
Similar toWT EC50s are observed for mutants that traffic to the plasma membrane (blue dia-
monds and green bars in S6 Fig) and for three mutants that do not traffic (blue diamonds and
red bar in S6 Fig), thus trafficking to the plasma membrane does not always correlate with either
maximum response or EC50 to isoprenaline, in the GFP-labeled filopodia assay. This could
reflect a distinct behavior of the protein in the two different cell types we use, OP6 cells to address
plasma membrane trafficking vs. HEK 293 for FLIPR assay. It would be informative to further
characterize some of our mutants with receptor binding assays in order to determine in more
detail the association and dissociation rates of the receptor as well as its density at the membrane.
We were surprised that the mutants with EC50s comparable to WT did not always achieve
maximum responses (see black box in Fig 8). This suggests a strict default on transduction
rather than binding to isoprenaline. An alternate view is that the mutants that poorly traffic to
the plasma membrane do not sufficiently deliver enough functional protein to the cell surface to
achieve significant responses. In addition, mutants that traffic well to the plasma membrane
show log-order differences in EC50 for isoprenaline but achieve the same maximum responses,
albeit lower thanWT (see differences along vertical axis in Fig 8). This is especially true for our
Ct mutants that have a higher affinity for isoprenaline, but have lost their capacity to interact
properly with the G-protein signal transduction machinery. Thus, within an in vivo setting with
sufficient or continuous ligand present, it is unclear if the affinity of the binding is as important
to the function of the receptor or if it is the maximum response obtainable (for example, perhaps
NtΔ9AA/ΔCt➔Y350/ΔC341 with an EC50 21 times higher thanWT and a maximum response
of 77% of WT would out perform NtΔ9AA/ mβ2AR/M71-Ct with an EC50 closer to WT (only
6 times higher) but with a lower maximum response of only 34% of WT).
TM7 and Ct domains of GPCRs are essential for G-protein transduction
All eleven mutants that have higher EC50 (poorer G-protein coupling) compared to WT
(EC50/EC50 of WT>2) have mutations in the Ct or the end of the TM7 (mutants in red
box in Fig 8). However, the maximum responses for these eleven mutants are variable. Trunca-
tions of the Ct to Y350 reduce the maximum response to as low as 67%. The swap of the
mβ2AR Ct with the Ct of M71 reduces the maximum response even further to 32%. The
ΔCt➔L339 and ΔCt➔E338 truncations reduce the maximum response even more to 27 and
19% of WT, respectively. Point mutations at the end of the 7th TM also increase the EC50 to
isoprenaline: the Y326A mutation reduces the maximum response slightly to 89% of mouse
WT and human/mouse C327R reduces the maximum response as low as 35% of humanWT
and to 58% of mouse WT.
Eight other mutations do not affect the EC50 for isoprenaline (EC50/EC50 of WT<2).
Those mutations are either located in the Nt of the protein and intracellular domains 2 and 3
(mutants in black box in Fig 8). Neither a reduction of size of the Nt nor the replacement of it
with the Nt of M71 affects the maximum response (Fig 8). Thus modifications of the Nt have
no discernable effects on signal transduction of the receptor. On the contrary, the double
mutant N6A and N15A, which abolishes the only N-glycosylation sites present in mβ2AR,
shows an increase in the maximum response (120% of WT, Fig 3). It is unclear if this increase
is due to the amino-acid substitutions or due to the lack of N-glycosylation sites. By contrast,
the double mutation RDY of the conserved DRY motif reduces the maximum response to iso-
prenaline to 60% for human RDY and 58% for mouse RDY (Fig 8), without affecting the EC50.
The reduction in maximum response is probably due to poor trafficking of the protein (see
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above). Finally, the mutation E268A in the 3rd intracellular loop of the receptor reduces its
maximum response to 51% of both human and mouse WT proteins.
Based on the recent crystallographic studies of human β2AR bound to agonists and frag-
ments of G-proteins, the human β2AR seems to interact with the α subunit of the stimulatory
G-protein for adenylyl cyclase (Gαs) via its intracellular loop 2, TM5 and TM6. There are no
direct interactions between human β2AR and Gβγ subunits [38]. Therefore, this study did not
reveal an interaction of TM7 or the Ct of human β2AR in binding to G-protein. However, as
proposed in this study, interactions with Gβy might occur within dimers of human β2AR in
the cell and could have been revealed in our study.
Conclusions
We have characterized over 30 mouse and human β2AR mutants (see S7 Fig). Our extensive
set of β2AR mutants reveals major roles for the end of the 7th TM domain and the Ct of the
β2AR on activity of the receptor in addition to the already described TM3-TM6 ionic lock
model for class A GPCRs [39]. We also reveal for the first time a possible role for Y326 as a traf-
ficking retention signal, as well as a synergistic negative interaction between the Nt and Ct of
an OR on trafficking. We describe that mutations can affect both activity and trafficking of the
mouse and human β2AR showing the difficulty to dissect those two components when using
mutants to study the physiology of the receptor, in particular as a surrogate of an OR. Interest-
ingly, we describe a new mβ2AR loss-of-function mutant for activity that retains proper plasma
membrane trafficking but fully fails to respond to isoprenaline. These observations provide a
stepping-stone for future mutations using our high-throughput screening assay as well as in
vivo studies on the physiology of β2AR and ORs.
Supporting Information
S1 Fig. Expression of NtΔ9AA/Y326A/ΔCt➔R328 and Y326A in OP6 cells. (A and B) Both
NtΔ9AA/Y326A/ΔCt➔R328 and Y326A express homogenously in OP6 cells and traffic to filo-
podia (arrow head in magnified pictures).
(EPS)
S2 Fig. 2D topology of M71-Nt/mβ2AR/M71-Ct chimeric receptor. The 2D topology of the
chimera M71-Nt/mβ2AR/M71-Ct was generated using the online software Topo2 (see Mate-
rial & Methods). Plasma membrane is symbolized by two horizontal lines with the extracellular
compartment on top and intracellular compartment on the bottom. Putative transmembrane
domains are located in between those two lines. The Nt and Ct of M71 are depicted as blue cir-
cles and the common residues between mβ2AR and M71 present at the limits of those regions
are shown in violet circles. The N-linked glycosylation site located in the Nt of the chimera is
showed in a black box.
(EPS)
S3 Fig. Correlation between The Number Of GFP-Labeled Filopodia Per Cell And The
Number Of Cells With1 GFP-Labeled Filopodium. All mutants presented in this study are
ranked based on increasing number of GFP-labeled filopodia per cell (1st axis, red and green
bars, mean +s.d.). Mutants that fail to traffic to filopodia (p<0.001, one-way ANOVA followed
by Scheffe tests, compared to WT) have red bars. Mutants that successfully traffic to filopodia
have green bars (p>0.001). On the 2nd axis is showed the number of cells with1 GFP-labeled
filopodium, blue diamonds for each mutant. All cells expressing mutants that successfully traf-
fic to filopodia but one (NtΔ9AA/Y326A/ΔCt➔R328 in black box) have more than one GFP-
labeled filopodium (blue diamonds at zero). One cell expressing NtΔ9AA/Y326A/ΔCt➔R328
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showed no GFP-labeled filopodium. By contrast, for all the mutants classified by our GFP-
labeled filopodia assay as non-trafficking mutants (red bars) at least 2/10 cells were observed
with1 GFP-labeled filopodium (blue diamonds 2 and red bars).
(EPS)
S4 Fig. Co-expression of mβ2AR mutants with RTP1S has no effect on mutants trafficking.
(A) Trafficking to filopodia of mutants that look like an odorant receptor is not affected by co-
expression of RTP1S. The average number of GFP-labeled filopodia per cell is showed (bars in
graph, mean +s.d.) as well as the number of cells with1 GFP-labeled filopodium (blue dia-
monds). means significantly different fromWT, one-way ANOVA followed by Scheffe
tests, p<0.001. n.s. means not significantly different fromWT, p>0.001. (B, C, D and E)
Mutants with shorter Ct that don’t traffic to filopodia are not rescued by co-expression of
RTP1S. (F) Trafficking of mutants for Y326 is also unaffected with co-expression of RTP1S. (H
and I) In particular no-NxS/Y326A/ΔCt➔R328 and M71-Nt/Y326A/ΔCt➔R328 are not res-
cued by co-expression of RTP1S. (G) Finally, trafficking of mβ2AR/M71 chimeric receptors is
also unchanged by co-expression of RTP1S. (J) In particular the trafficking of the chimeric
receptor M71-Nt/mβ2AR/M71-Ct is not rescued by co-expression of RTP1S.
(EPS)
S5 Fig. Correlation between trafficking to filopodia and maximum response to isoprena-
line. All mutants presented in this study are sorted in increasing number of GFP-labeled filo-
podia per cell (1st axis, red and green bars, mean +s.d.). Mutants that fail to traffic to filopodia
(p<0.001, one-way ANOVA followed by Scheffe tests, compared to WT) have red bars.
Mutants that successfully traffic to filopodia have green bars (p>0.001). On the 2nd axis is indi-
cated the maximum response to isoprenaline as percentage of WT. Maximum responses to iso-
prenaline close to WT (from 97 to 103%) are showed as blue diamonds, higher response
(120%) as a magenta diamond, lower responses (from 19 to 90%) as black diamonds and no
response as red diamonds. Trafficking does not fully correlate with the maximum of the trans-
duction response obtained.
(EPS)
S6 Fig. Correlation between trafficking to filopodia and affinity to isoprenaline. All
mutants presented in this study are sorted in increasing number of GFP-labeled filopodia per
cell (1st axis, red and green bars, mean +s.d.). Mutants that fail to traffic to filopodia (p<0.001,
one-way ANOVA followed by Scheffe tests, compared to WT) have red bars. Mutants that suc-
cessfully traffic to filopodia have green bars (p>0.001). On the 2nd axis is indicated the EC50 of
the mutant for isoprenaline relative to the EC50 of WT on a log scale. Affinity similar to WT
(i.e. ratio close to 1, from 0.8 to 2.1) is showed as blue diamonds, and lower affinity compare to
WT (i.e. ratio>1, from 4 to 78) is showed as black diamond.
(EPS)
S7 Fig. Overview of mβ2AR results. In the summary table is showed a brief description of the
GPCR analyzed (1st column) as well as a 2D schematic of the GPCR (2nd column). 3rd column
indicates if the receptor successfully traffic to the plasma membrane, as revealed by the GFP-
labeled filopodia assay. 4th and 5th columns indicate its transduction efficacy and affinity com-
pare to the WT β2AR::GFP.
(EPS)
S1 Text. Nucleotide and amino acid sequences used in mutational analysis.DNA and protein
sequences for mouse β2AR, human β2AR, M71, linker, GFP andmCherry and their plasmid names.
(DOCX)
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